{"nctId":"NCT05299359","briefTitle":"A Single Heterologous Booster Vaccination Study of TAK-019 in Healthy Japanese Adults (COVID-19)","startDateStruct":{"date":"2022-04-15","type":"ACTUAL"},"conditions":["Coronavirus Disease (COVID-19)"],"count":150,"armGroups":[{"label":"TAK-019 Main Part","type":"EXPERIMENTAL","interventionNames":["Biological: TAK-019"]},{"label":"TAK-019 Extension Part","type":"EXPERIMENTAL","interventionNames":["Biological: TAK-019"]}],"interventions":[{"name":"TAK-019","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nMAIN PART:\n\n1. Healthy Japanese male and female adult participants aged \\>= 20 years of age at the time of signing of informed consent.\n2. Participant who completed 2 doses primary vaccinations with another specified mRNA vaccine which is available in Japan 6 to 12 months prior to the trial vaccination.\n\n   EXTENSION PART:\n3. Participants who received the first trial vaccination at least 5 months earlier and are currently enrolled in the Main Part (ie, not have withdrawn or discontinued early).\n\nExclusion Criteria:\n\nMAIN PART:\n\n1. Participants who received any other SARS-CoV-2 vaccine (except for the specified mRNA vaccine) or other experimental novel coronavirus vaccine prior to the trial.\n2. Participant who received a booster vaccination (i.e. 3rd dose)\n3. Participants who have close contact of anyone known to have COVID-19 within 14 days prior to the trial vaccination.\n4. Participants who were tested positive for SARS-CoV-2 prior to the trial.\n5. Participants who have traveled outside of Japan in the 30 days prior to the trial participation.\n6. Participants with a clinically significant active infection or oral temperature \\>= 38 degree Celsius within 3 days of the intended date of the first single booster vaccination.\n7. Participants with body mass index (BMI) greater than or equal to 30 kg/m\\^2 (BMI= weight in kg/ height in meters\\^2)\n\n   EXTENSION PART:\n8. Participants with a clinically significant active infection or oral temperature \\>=38 degree Celsius within 3 days of the intended date of the second single booster vaccination.","healthyVolunteers":true,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Main Part: Geometric Mean Titers (GMT) Ratio of Neutralizing Antibody Titers to the Ancestral Strain (Wild-type Virus) on Day 15 Compared With That Observed on Day 36 in Participants From the TAK-019-1501 Study","description":"GMT was the immunogenicity outcome expressed as reciprocal antibody titer with average for each group. Titer values was measured as below lower limit of quantification (LLOQ) were imputed to a value that was half of the LLOQ. LLOQ was equal to 20. GMT for each group and GMT ratio of neutralizing antibody titers to the ancestral strain (wild-type virus) on Day15 after a single booster vaccination (14 days after the booster vaccination) compared with that observed on Day 36 (14 days after the second vaccination) in participants from the TAK-019-1501 study (NCT04712110) were reported. GMT ratio was calculated with GMT of TAK-019-3001 on Day 15 divided by GMT of TAK-019-1501 study on Day 36. Here, ELISA is Enzyme-linked immunosorbent assay.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1143.9","spread":null},{"groupId":"OG001","value":"884.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Main Part: Percentage of Participants With Reported Solicited Local Adverse Events (AEs) for 7 Days Following the First Single Booster Vaccination","description":"AE was defined as any untoward medical occurrence in a clinical investigation participant administered an investigational medicinal product (IMP); it did not necessarily have to have a causal relationship with IMP administration. Reported solicited local AEs were defined as injection site pain, tenderness, erythema/redness, induration, and swelling.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Main Part: Percentage of Participants With Solicited Systemic AEs for 7 Days Following the First Single Booster Vaccination","description":"Solicited systemic AEs were defined as fever, fatigue, malaise, myalgia, arthralgia, nausea/vomiting, and headache.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Main Part: Percentage of Participants With Unsolicited AEs for 28 Days Following the First Single Booster Vaccination","description":"Unsolicited AEs defines as other AEs than solicited local AEs and solicited systemic AEs.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.67","spread":null}]}]}]},{"type":"PRIMARY","title":"Main Part: Percentage of Participants With Solicited and Unsolicited Serious Adverse Events (SAE) Until Day 29","description":"An SAE was defined as any untoward medical occurrence that: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent or significant disability/incapacity, leads to a congenital anomaly/birth defect in the offspring of a participant, or is an important medical event. Solicited SAEs and unsolicited SAEs were reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Main Part: Percentage of Participants With Adverse Event of Special Interest (AESI) Until Day 29","description":"An AESI was defined as AEs that will be specifically highlighted to the Investigator. AESIs for the study included the Potential Immune Mediated Medical Conditions (PIMMC) and AEs specific to COVID-19. PIMMC is categorized as following; neuroinflammatory disorders, musculoskeletal and connective tissue disorders, vasculitides, gastrointestinal disorders, hepatic disorders, renal disorders, cardiac disorders, skin disorder, hematologic disorders, metabolic disorders, and other disorders.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Main Part: Percentage of Participants With Medically-Attended Adverse Events (MAAEs) Until Day 29","description":"MAAEs were defined as AEs leading to an unscheduled visit to or by a healthcare professional including visits to an emergency department, but not fulfilling seriousness criteria.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Main Part: Percentage of Participants With Any AE Leading to Withdrawal From the Trial Until Day 29","description":"Percentage of participants with any AE leading to withdrawal from the trial until Day 29 was reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Main Part: Percentage of Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Infection Until Day 29","description":"Percentage of participants with SARS-CoV-2 infection until Day 29 of the main part of the trial were reported in this outcome measure.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Main Part: GMT of Serum Immunoglobulin G (IgG) Antibody Levels to SARS-CoV-2 Recombinant Spike (rS) Protein on Day 8, 15, 29, 91, 181, and 366","description":"GMT was the immunogenicity outcome expressed as reciprocal antibody titer with average. Titer values was measured as below LLOQ were imputed to a value that was half of the LLOQ. LLOQ was equal to 200 EU/mL.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24705.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35202.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36138.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26420.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20246.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31369.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Main Part: Geometric Mean Fold Rise (GMFR) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 8, 15, 29, 91, 181, and 366","description":"GMFR was calculated as the ratio of the post-vaccination titer level to the baseline titer level. Where baseline was defined as the last measurement taken before the first dose of trial vaccination.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.96","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.28","spread":null}]}]}]},{"type":"SECONDARY","title":"Main Part: Seroconversion Rate (SCR) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 8, 15, 29, 91, 181, and 366","description":"SCR was defined as percentage of participants with 4-fold or more rises from baseline in titer. Baseline was defined as the last measurement taken before the first dose of trial vaccination.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Main Part: GMT of Serum Neutralizing Antibody Titers to the Ancestral Strain (Wild-type Virus) on Day 8, 15, 29, 91, 181, and 366","description":"The neutralization titer was expressed as the reciprocal of the highest dilution at which greater than or equal to (\\>=) 50 percent (%) of the replicate wells were protected from infection (microneutralization \\[MN\\] with an inhibitory concentration of 50% \\[MN50\\]). GMT was the immunogenicity outcome expressed as reciprocal antibody titer with average. Titer values was measured as below LLOQ were imputed to a value that was half of the LLOQ where LLOQ was equal to 20.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"729.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1143.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"775.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"656.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"844.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1424.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Main Part: GMFR of Serum Neutralizing Antibody Titers to the Ancestral Strain (Wild-type Virus) on Day 8, 15, 29, 91, 181, and 366","description":"The neutralization titer was expressed as the reciprocal of the highest dilution at which \\>=50% of the replicate wells were protected from infection (MN50). GMFR was calculated as the ratio of the post-vaccination titer level to the baseline titer level. Baseline was defined as the last measurement taken before the first dose of trial vaccination.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.79","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.90","spread":null}]}]}]},{"type":"SECONDARY","title":"Main Part: SCR of Serum Neutralizing Antibody Titters to the Ancestral Strain (Wild-type Virus) on Day 8, 15, 29, 91, 181, and 366","description":"The neutralization titer was expressed as the reciprocal of the highest dilution at which greater than or equal to (\\>=) 50% of the replicate wells were protected from infection (MN50). SCR was defined as percentage of participants with 4-fold or more rises in from baseline. Baseline was defined as the last measurement taken before the first dose of trial vaccination.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Main Part: Percentage of Participants With Solicited and Unsolicited SAEs Throughout the Main Part of Trial","description":"An SAE was defined as any untoward medical occurrence that: Results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent or significant disability/incapacity, leads to a congenital anomaly/birth defect in the offspring of a participant, or is an important medical event. Solicited SAEs and unsolicited SAEs were reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Main Part: Percentage of Participants With AESI Throughout the Main Part of Trial","description":"An AESI was defined as AEs that will be specifically highlighted to the Investigator. AESIs for the study included the PIMMC and AEs specific to COVID-19. PIMMC is categorized as following; neuroinflammatory disorders, musculoskeletal and connective tissue disorders, vasculitides, gastrointestinal disorders, hepatic disorders, renal disorders, cardiac disorders, skin disorder, hematologic disorders, metabolic disorders, and other disorders.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Main Part: Percentage of Participants With MAAEs Throughout the Main Part of Trial","description":"MAAEs were defined as AEs leading to an unscheduled visit to or by a healthcare professional including visits to an emergency department, but not fulfilling seriousness criteria.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Main Part: Percentage of Participants With Any AE Leading to Participant's Withdrawal From the Trial From the Day of the First Single Booster Vaccination Throughout the Main Part of Trial","description":"Percentage of participants with any AE leading to participant's withdrawal from the trial from the day of the first single booster vaccination throughout the main part of trial was reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Main Part: Percentage of Participants With SARS-CoV-2 Infection Throughout the Main Part of Trial","description":"Percentage of participants with SARS-CoV-2 infection throughout the main part of trial was reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Extension Part: GMT of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 15, 29, 91, 181, and 366","description":"GMT was the immunogenicity outcome expressed as reciprocal antibody titer with average. Titer values was measured as below LLOQ were imputed to a value that was half of the LLOQ. LLOQ was equal to 200 EU/mL.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"105057.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88154.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61090.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46199.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62823.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Extension Part: GMFR of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Extension Part Day 15, 29, 91, 181, and 366","description":"The GMFR was calculated as the ratio of the post-second-booster-vaccination titer level to extension part baseline titer level. Where extension part baseline was defined as last measurement taken before the second booster vaccination.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.33","spread":null}]}]}]},{"type":"SECONDARY","title":"Extension Part: Seroconversion Rate (SCR) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Extension Part Day 15, 29, 91, 181, and 366","description":"SCR was defined as percentage of participants with 4-fold or more rises in titer from extension part baseline. Where extension part baseline was defined as last measurement taken before the second booster vaccination.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Extension Part: GMT of Serum Neutralizing Antibody Titers to the Ancestral Strain (Wild-type Virus) on Extension Part Day 15, 29, 91, 181, and 366","description":"The neutralization titer was expressed as the reciprocal of the highest dilution at \\>= 50% of the replicate wells were protected from infection (MN50). GMT was the immunogenicity outcome expressed as reciprocal antibody titer with average. Titer values was measured as below LLOQ were imputed to a value that was half of the LLOQ where LLOQ was equal to 20.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1716.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1732.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1255.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1360.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"660.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Extension Part: GMFR of Serum Neutralizing Antibody Titers to the Ancestral Strain (Wild-type Virus) on Extension Part Day 15, 29, 91, 181, and 366","description":"The neutralization titer was expressed as the reciprocal of the highest dilution at \\>= 50% of the replicate wells were protected from infection (MN50). The GMFR was calculated as the ratio of the post-second-booster-vaccination titer level to extension part baseline titer level. Where extension part baseline was defined as last measurement taken before the second booster vaccination.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.04","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.05","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.16","spread":null}]}]}]},{"type":"SECONDARY","title":"Extension Part: SCR of Serum Neutralizing Antibody Titers to the Ancestral Strain (Wild-type Virus) on Extension Part Day 15, 29, 91, 181, and 366","description":"The neutralization titer was expressed as the reciprocal of the highest dilution at \\>= 50% of the replicate wells were protected from infection (MN50). SCR was defined as percentage of participants with 4-fold or more rises in titer from extension part baseline.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Extension Part: Percentage of Participants With Reported Solicited Local AEs for 7 Days Following the Second Single Booster Vaccination in Extension Part","description":"AE was defined as any untoward medical occurrence in a clinical investigation participant administered an investigational medicinal product (IMP); it did not necessarily have to have a causal relationship with IMP administration. Reported solicited local AEs were defined as injection site pain, tenderness, erythema/redness, induration, and swelling.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Extension Part: Percentage of Participants With Solicited Systemic AEs for 7 Days Following the Second Single Booster Vaccination in Extension Part","description":"Solicited systemic AEs included were defined as fever, fatigue, malaise, myalgia, arthralgia, nausea/vomiting and headache.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Extension Part: Percentage of Participants With Unsolicited AEs for 28 Days Following the Second Single Booster Vaccination in Extension Part","description":"Unsolicited AEs defined as AEs other than solicited local AEs and solicited systemic AEs.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Extension Part: Percentage of Participants With Solicited and Unsolicited SAEs Until Extension Part Day 29","description":"An SAE was defined as any untoward medical occurrence that: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, leads to a congenital anomaly/birth defect in the offspring of a participant, or is an important medical event. Solicited SAEs and unsolicited SAEs were reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Extension Part: Percentage of Participants With AESIs Until Extension Part Day 29","description":"An AESI was defined as AEs that will be specifically highlighted to the investigator. AESIs for the study included the PIMMC and AEs specific to COVID-19. PIMMC is categorized as following; neuroinflammatory disorders, musculoskeletal and connective tissue disorders, vasculitides, gastrointestinal disorders, hepatic disorders, renal disorders, cardiac disorders, skin disorder, hematologic disorders, metabolic disorders, and other disorders.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Extension Part: Percentage of Participants With MAAEs Until Extension Part Day 29","description":"MAAEs were defined as AEs leading to an unscheduled visit to or by a healthcare professional including visits to an emergency department, but not fulfilling seriousness criteria.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Extension Part: Percentage of Participants With Any AEs Leading to Withdrawal From the Trial Until Extension Part Day 29","description":"Percentage of participants with any AEs leading to withdrawal from the trial until extension part Day 29 was reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Extension Part: Percentage of Participants With SARS-CoV-2 Infection Until Extension Part Day 29","description":"Percentage of participants with SARS-CoV-2 infection until extension part Day 29 was reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Extension Part: Percentage of Participants With Solicited and Unsolicited SAEs Throughout the Extension Part of the Trial","description":"An SAE was defined as any untoward medical occurrence that: Results in death, Is life-threatening, Requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent or significant disability/incapacity, Leads to a congenital anomaly/birth defect in the offspring of a participant, or Is an important medical event. Solicited SAEs and unsolicited SAEs were reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Extension Part: Percentage of Participants With AESIs Throughout the Extension Part of the Trial","description":"An AESI was defined as AEs that will be specifically highlighted to the Investigator. AESIs for the study included the PIMMC and AEs specific to COVID-19. PIMMC is categorized as following; neuroinflammatory disorders, musculoskeletal and connective tissue disorders, vasculitides, gastrointestinal disorders, hepatic disorders, renal disorders, cardiac disorders, skin disorder, hematologic disorders, metabolic disorders, and other disorders.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Extension Part: Percentage of Participants With MAAEs Throughout the Extension Part of the Trial","description":"MAAEs were defined as AEs leading to an unscheduled visit to or by a healthcare professional including visits to an emergency department, but not fulfilling seriousness criteria.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Extension Part: Percentage of Participants With Any AEs Leading to Withdrawal From the Trial From the Day of the Second Single Booster Vaccination Throughout the Extension Part of the Trial","description":"Percentage of participants with any AEs leading to withdrawal from the trial from the day of the second single booster vaccination throughout the extension part of the trial was reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Extension Part: Percentage of Participants With SARS-CoV-2 Infection Throughout the Extension Part of Trial","description":"Percentage of participants with SARS-CoV-2 infection throughout the extension part of trial was reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":150},"commonTop":["Tenderness","Injection site pain","Malaise","Headache","Myalgia"]}}}